
## CITATION REPORT List of articles citing



DOI: 10.1161/circresaha.121.318172 Circulation Research, 2021, 128, 1421-1434.

Source: https://exaly.com/paper-pdf/80340283/citation-report.pdf

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
139	Heart Failure 2021: A Compendium of Translational Success. <i>Circulation Research</i> , <b>2021</b> , 128, 1419-1420	15.7	O
138	Effects of Renal Denervation on the Enhanced Renal Vascular Responsiveness to Angiotensin II in High-Output Heart Failure: Angiotensin II Receptor Binding Assessment and Functional Studies in Ren-2 Transgenic Hypertensive Rats <b>2021</b> , 9,		1
137	Endpoints in Heart Failure Drug Development <b>2022</b> , 8, e01		O
136	Inflammatory Markers and Risk of Heart Failure With Reduced to Preserved Ejection Fraction <b>2022</b>		3
135	Neutrophil extracellular traps in cardiac hypertrophy: a KLF2 perspective 2022, 132,		1
134	HMGB1-Promoted Neutrophil Extracellular Traps Contribute to Cardiac Diastolic Dysfunction in Mice <b>2022</b> , 11, e023800		1
133	Incidence, prevalence, and characteristics of heart failure among patients with multiple sclerosis: A systematic review and meta-analysis <b>2022</b> , 59, 103665		1
132	Regulation of calcium handling by autophagy: a novel mechanism limiting cardiac hypertrophy and dysfunction?. <b>2022</b> ,		
131	ATTR Epidemiology, Genetics, and Prognostic Factors <b>2022</b> , 18, 17-26		3
130	Nanoengineered Sprayable Therapy for Treating Myocardial Infarction 2022,		O
129	Differences in Outpatient Health Care Utilization 12 Months after COVID-19 Infection by Race/Ethnicity and Community Social Vulnerability <b>2022</b> , 19,		1
128	A low-cost, paper fluidic platform to detect B-type Natriuretic Peptide (BNP) for Congestive Heart Failure (CHF). <b>2022</b> ,		
127	Variability in Coronary Artery Disease Testing for Patients With New-Onset Heart Failure <b>2022</b> , 79, 849	9-860	0
126	Immune response in heart transplantation: a bibliometric analysis <b>2022</b> , 14, 635-645		
125	Underdiagnosis of Ischemic Heart Disease in New-Onset Heart Failure: A Call to Action <b>2022</b> , 79, 861-8	63	
124	Middle age serum sodium levels in the upper part of normal range and risk of heart failure 2022,		1
123	Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis 2022,		О

122	Editorial: Epigenetics in Heart Failure Developing: The Orchestra of Etiology and Comorbidities <b>2022</b> , 9, 869613	
121	Prediction of Adverse Post-Infarction Left Ventricular Remodeling Using a Multivariate Regression Model <b>2022</b> , 12,	O
120	Neutrophil to Lymphocyte Ratio (NLR) as an Easily Accessible Parameter for Monitoring Tacrolimus Overdose after Heart Transplantation-Experimental Study <b>2021</b> , 12,	1
119	Genome-wide association analysis and Mendelian randomization proteomics identify novel protein biomarkers and drug targets for primary prevention of heart failure.	O
118	Serum Chloride Is Inversely Associated With 3 Months Outcomes in Chinese Patients With Heart Failure, a Retrospective Cohort Study <b>2022</b> , 9, 855053	
117	Prehospitalization Symptom Perceptions, Lay Consultations, and Treatment-Seeking for Acute Decompensating Heart Failure: Implications for Nursing Practice. <b>2022</b> ,	
116	Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes <b>2022</b> , 109927	3
115	[Applicability of the load dynamometric test and speckle tracking echocardiography in the heart failure with preserved ejection fraction diagnosis] <b>2022</b> , 62, 36-43	
114	Point-of-care heart failure platform: where are we now and where are we going to?. 2022,	2
113	Heart FailureDo We Need New Drugs or Have Them Already? A Case of Coenzyme Q10. <b>2022</b> , 9, 161	
112	Diabetes Is the Strongest Predictor of Limited Exercise Capacity in Chronic Heart Failure and Preserved Ejection Fraction (HFpEF). <b>2022</b> , 9,	0
111	Serum copper-to-zinc ratio is associated with heart failure and improves risk prediction in middle-aged and older Caucasian men: A prospective study. <b>2022</b> ,	2
110	Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.	2
109	Quantitative Assessment of Aortic Hemodynamics for Varying Left Ventricular Assist Device Outflow Graft Angles and Flow Pulsation.	O
108	A multimodal parallel method for left ventricular dysfunction identification based on phonocardiogram and electrocardiogram signals synchronous analysis. <b>2022</b> , 19, 9612-9635	1
107	The Art of Reprogramming for Regenerative Medicine. 10,	
106	Gut Microbiota and Sex Hormones: Crosstalking Players in Cardiometabolic and Cardiovascular Disease. <b>2022</b> , 23, 7154	О
105	Efficacy and safety of vitamin-K antagonists and direct oral anticoagulants for stroke prevention in patients with heart failure and sinus rhythm: an updated systematic review and meta-analysis of randomized clinical trials. 174749302211091	O

104	Physiologic Data-Driven Iterative Learning Control for Left Ventricular Assist Devices. 9,	0
103	Beyond perfusion imaging.	
102	The heart is where AAV9 lies.	
101	Gamma-interferon-inducible lysosomal thiol reductase maintains cardiac immuno-metabolic homeostasis in heart failure.	O
100	An Integrative Comparative Study Between Digoxin and Amiodarone as an Emergency Treatment for Patients With Atrial Fibrillation With Evidence of Heart Failure: A Systematic Review and Meta-Analysis. <b>2022</b> ,	
99	A Data Mining-Based Study on Medication Rules of Chinese Herbs to Treat Heart Failure with Preserved Ejection Fraction.	
98	Safety and efficacy considerations amongst the elderly population in the updated treatment of heart failure: a review. 1-13	О
97	Burden of heart failure in primary healthcare. <b>2022</b> , 54, 102413	1
96	Ethical and Legal Concerns Associated With Withdrawing Mechanical Circulatory Support: A U.S. Perspective. 9,	
95	A novel IMFET biosensor strategy for Interleukin-10 quantification for early screening heart failure disease in saliva.	O
94	Sex mismatch following heart transplantation in the United States: Characteristics and impact on outcomes.	О
93	Pioglitazone-incorporated microspheres targeting macrophage polarization alleviates cardiac dysfunction after myocardial infarction.	O
92	Assessment of Malnutrition in Heart Failure and Its Relationship with Clinical Problems in Brazilian Health Services. <b>2022</b> , 19, 10090	0
91	Effectiveness of atrial fibrillation ablation in heart failure across the entire spectrum of left ventricular ejection fraction.	O
90	Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond. <b>2022</b> , 9, 256	1
89	The diagnostic value of peroxisome proliferator-activated receptor-Izoactivator-1#n identifying different chronic heart failure phenotypes. 9,	O
88	Cost-effective heart failure management: Meta-analysis of IV iron therapy in iron-deficient heart failure patients. <b>2022</b> , 22, 100204	0
87	Ivabradine treatment lowers blood pressure and promotes cardiac and renal protection in spontaneously hypertensive rats. <b>2022</b> , 308, 120919	1

86	Bibliometric Analysis of Traditional Chinese Medicine Research on Heart Failure in the 21st Century Based on the WOS Database.	0
85	Analysis of the Application Value of Echocardiography Combined with CK-MB, Alb, and CysC in the Prognosis Assessment of Patients with Chronic HF. <b>2022</b> , 2022, 1-6	O
84	Development and validation of a predictive model for adverse left ventricular remodeling in NSTEMI patients after primary percutaneous coronary intervention. <b>2022</b> , 22,	O
83	Essen Stroke Risk Score Predicts Clinical Outcomes in Heart Failure Patients With Preserved Ejection Fraction: Evidence From the TOPCAT trial.	O
82	New Strategies to Prevent Rehospitalizations for Heart Failure.	O
81	The effectiveness of eHealth self-management interventions in patients with chronic heart failure: Protocol for a systematic review and meta-analysis. <b>2022</b> , 17, e0268446	O
80	Heart Failure and Cardiomyopathies: CT and MR from Basics to Advanced Imaging. 2022, 12, 2298	O
79	Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis. <b>2022</b> ,	O
78	Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: A systematic review and meta-analysis. 9,	O
77	Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis. <b>2022</b> , 17, e0275311	O
76	Risk of death associated with incident heart failure in patients with known or suspected chronic coronary syndrome.	0
75	Clinical outcomes of opioid administration in acute and chronic heart failure: A meta-analysis. <b>2022</b> , 102636	O
74	Donation After Circulatory Death: A New Frontier.	1
73	Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy. <b>2022</b> , 23, 13274	O
72	Clinical efficacy of Qili Qiangxin Capsule combined with exercise rehabilitation in the treatment of chronic heart failure. <b>2022</b> ,	0
71	Optimized dosing of guideline-directed medical therapies is essential in heart failure with reduced ejection fraction. <b>2022</b> ,	Ο
70	Promising directions in the treatment of chronic heart failure: improving old or developing new ones?. <b>2022</b> , 21, 181-197	0
69	Exploring the triggers of psychological distress among Jordanian patients with heart failure: a phenomenological study.	O

68	Material property alterations for phenotypes of heart failure with preserved ejection fraction: A numerical study of subject-specific porcine models. 10,	Ο
67	Efficacy of Xinbao pill on chronic heart failure: Study protocol of a multicenter, randomized, double-blind, placebo-controlled trial. 13,	O
66	Left Atrial Reverse Remodeling in Dilated Cardiomyopathy. 2022,	O
65	Non-Contact Molecular Chemical Imaging Assessment of Tissue Congestion: A Validation Study Compared to MRI.	Ο
64	The Role of Depression on Treatment Adherence in Patients with Heart Failure Systematic Review of the Literature.	Ο
63	Natriuretic peptide testing and heart failure diagnosis in primary care: diagnostic accuracy study. BJGP.202	22.0278
62	Impact of myeloid differentiation protein 1 on cardiovascular disease. 2023, 157, 114000	0
61	Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes.	O
60	Empagliflozin: A Review in Symptomatic Chronic Heart Failure.	0
59	Estimated pulse wave velocity and incident heart failure and its subtypes: Findings from the multi-ethnic study of atherosclerosis. <b>2023</b> , 25, 100238	O
58	Outcomes of Patients with Heart Failure followed in a Cardiological Setting to Parakou from 2016 to 2020. <b>2022</b> , 12, 490-506	0
57	MARKER DIAGNOSTIC HEART FAILURE PROGRESSION IN THE POST-INFARCTION PERIOD. <b>2022</b> , 75, 2476-7	2480 <sub>0</sub>
56	p63 silencing induces epigenetic modulation to enhance human cardiac fibroblast to cardiomyocyte-like differentiation. <b>2022</b> , 12,	1
55	Mixed Imaging Sequences for Improved Spatiotemporal Resolution in Cardiac Imaging. 2022,	O
54	Comparative Analysis of Non-Coding RNA Transcriptomics in Heart Failure. 2022, 10, 3076	2
53	Opioids for treating refractory dyspnea in patients with heart failure: A protocol for systematic review and meta-analysis. <b>2022</b> , 101, e31699	O
52	Well-Being, Physical Activity, and Social Support in Octogenarians with Heart Failure during COVID-19 Confinement: A Mixed-Methods Study. <b>2022</b> , 19, 15316	О
51	Risk of Mortality Prediction Involving Time-Varying Covariates for Patients with Heart Failure Using Deep Learning. <b>2022</b> , 12, 2947	0

50	Plasma metabolomic analysis reveals the therapeutic effects of Jiashen tablets on heart failure. 9,	O
49	Elevated circulating level of Eminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors. <b>2022</b> , 21,	O
48	Biomarkers in Heart Failure: From Research to Clinical Practice. 2023, 43, 225-236	3
47	Assessment of Myocardial Texture. <b>2022</b> , 80, 2202-2204	O
46	The risk of myocardial infarction and heart failure in patients with gouty arthritis: A systematic review and meta-analysis.	O
45	A new role for an old drug: Acetazolamide in decompensated heart failure.	O
44	Editorial: Novel phenotyping and risk stratification strategies for heart failure. 9,	0
43	GPR30 Alleviates Pressure Overload-Induced Myocardial Hypertrophy in Ovariectomized Mice by Regulating Autophagy. <b>2023</b> , 24, 904	0
42	Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure. 9,	1
41	Reverse Remodeling and Functional Improvement of Left Ventricle in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan: Comparison between Non-Ischemic and Ischemic Etiology. <b>2023</b> , 12, 621	O
40	GC-MS Techniques Investigating Potential Biomarkers of Dying in the Last Weeks with Lung Cancer. <b>2023</b> , 24, 1591	O
39	Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value. 2023, 81, 4-14	O
38	Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction. <b>2023</b> , 28, 107424842211463	O
37	Bibliometric analysis of traditional Chinese medicine research on heart failure in the 21st century based on the WOS database. <b>2023</b> , 9, e12770	O
36	Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: Studies in 5/6 nephrectomized rats with aorto-caval fistula. <b>2023</b> , 158, 114157	0
35	Evaluation of potential biomarkers for traditional Chinese medicine-based chronic heart failure syndromes: A case-control study. <b>2023</b> , 58, 102222	O
34	Graphene Nanosheets Mediate Efficient Direct Reprogramming into Induced Cardiomyocytes. <b>2022</b> , 18, 2171-2182	О
33	Cardiovascular health metrics and risk of heart failure in a Finnish population: a prospective cohort study.	O

32	Revised Harris <b>B</b> enedict Equation: New Human Resting Metabolic Rate Equation. <b>2023</b> , 13, 189	O
31	One-step impedimetric NT-proBNP aptasensor targeting cardiac insufficiency in artificial saliva. <b>2023</b> , 256, 124280	O
30	Research Progress in Iron Metabolism in Heart Failure. <b>2023</b> , 13, 4616-4622	O
29	Predictors of physical activity behavior change among patients with heart failure enrolled in home-based cardiac rehabilitation intervention. <b>2023</b> , 61, 16-21	O
28	Xinbao Pill attenuated chronic heart failure by suppressing the ubiquitination of EAdrenergic Receptors. <b>2023</b> , 154830	O
27	Quantitative Assessment of Aortic Hemodynamics for Varying Left Ventricular Assist Device Outflow Graft Angles and Flow Pulsation.	O
26	Cardiovascular utility of single cell RNA-Seq. <b>2023</b> , 38, 193-200	O
25	Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype. <b>2023</b> , 324, H443-H460	1
24	The role of SGLT-2 inhibitors on health-related quality of life, exercise capacity, and volume depletion in patients with chronic heart failure: a meta-analysis of randomized controlled trials.	О
23	A time-series minimally invasive transverse aortic constriction mouse model for pressure overload-induced cardiac remodeling and heart failure. 10,	O
22	Association of 48-h net fluid status with change in renal function and dyspnea among patients with decompensated heart failure: A pooled cohort analysis of three acute heart failure trials.	O
21	PGRMC1 Ablation Protects from Energy-Starved Heart Failure by Promoting Fatty Acid/Pyruvate Oxidation. <b>2023</b> , 12, 752	O
20	Acute Cardiorenal Syndrome: An Update. Publish Ahead of Print,	O
19	Prevalence of Violence against Providers in Heart and Lung Transplant Programs. <b>2023</b> , 20, 4805	O
18	Identifying the patient with heart failure to be treated with vericiguat. 1-9	O
17	Heart Failure With Preserved Ejection Fraction. <b>2023</b> , 329, 827	O
16	Burden of Illness beyond Mortality and Heart Failure Hospitalizations in Patients Newly Diagnosed with Heart Failure in Spain According to Ejection Fraction. <b>2023</b> , 12, 2410	О
15	Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences. <b>2023</b> , 15, 1002	O

## CITATION REPORT

14	A Historical Review of Mechanical Circulatory Support.	О
13	Mechanical dispersion is a superior echocardiographic feature to predict exercise capacity in preclinical and overt heart failure with preserved ejection fraction.	Ο
12	Pharmacist- and Nurse-Led Medical Optimization in Heart Failure: A Systematic Review and Meta-Analysis. <b>2023</b> ,	O
11	Outcomes of Heart Failure Related Hospitalizations During the COVID-19 Pandemic. 2023,	Ο
10	Does sex affect the risk of 30-day all-cause mortality in cardiogenic shock?. <b>2023</b> ,	О
9	Atrioventricular node dysfunction in pressure overload-induced heart failureIhvolvement of the immune system and transcriptomic remodelling. 14,	O
8	Effect of C-reactive protein on the risk of Heart failure: a mendelian randomization study. 2023, 23,	O
7	Nonsteroidal Anti-Inflammatory Drugsland Type 2 Diabetes. <b>2023</b> , 81, 1471-1473	Ο
6	Identification of signature genes and functional genetic variants in heart failure by integrated bioinformatics analysis.	0
5	Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: the Gemi-Heart study.	0
4	Cardioprotective role of a magnolol and honokiol complex in the prevention of doxorubicin-mediated cardiotoxicity in adult rats.	O
3	Left Ventricular Assist Device as a Destination Therapy: Current Situation and the Importance of Patient Selection. <b>2023</b> , 13, 1065	O
2	An evidence map of systematic reviews on models of outpatient care for patients with chronic heart diseases. <b>2023</b> , 12,	О
1	Sex differences in the impact of physical frailty on outcomes in heart failure. <b>2023</b> , 61, 66-71	O